EMA Panel Recommends New Indication for Novartis' Blockbuster Drug Cosentyx

Key Facts

The European Medicines Agency (EMA) panel issued a positive opinion recommending a new indication for Novartis' drug Cosentyx. Benzinga reported that the Committee for Medicinal Products for Human Use (CHMP) recommended expanding the approved uses for the blockbuster treatment following a review of clinical data supporting its efficacy for an additional medical indication.

Novartis shares, trading under the ticker NVS, closed at $160.25 on November 12, 2026. The stock saw a session range between a low of $159.93 and a high of $161.32 on that date. This regulatory progress in a major market typically supports long-term revenue growth for the pharmaceutical firm.